Skip to main content
. Author manuscript; available in PMC: 2020 Apr 22.
Published in final edited form as: Gastroenterology. 2020 Jan 13;158(5):1450–1461. doi: 10.1053/j.gastro.2020.01.006
6. In adult outpatients with moderate-severe ulcerative colitis, the AGA suggests early use of biologic agents with or without immunomodulator therapy, rather than gradual step up after failure of 5-aminosalicylates. (Conditional recommendation, very low quality evidence)
Comment: Patients, particularly those with less severe disease, who place higher value on the safety of 5-ASA therapy, and lower value on the efficacy of biologic agents, may reasonably choose gradual step therapy with 5-ASA therapy.